Molecular Imaging and Therapeutics (MI&T)
The Molecular Imaging and Therapeutics (MI&T) division, at UCSF Department of Radiology & Biomedical Imaging, oversees the clinical practice of traditional nuclear medicine, including multimodality PET/CT and PET/MR, and stewards the application of molecular therapeutic agents for our patients. The division will also work closely with the Chemistry, Probes and Molecular Therapy (CPMT) Specialized Resources Group within the department, as well as with clinicians and researchers in other departments such as oncology, cardiology and neuroscience, to usher in a new generation of imaging and treatment modalities.
Why choose Nuclear Medicine / Molecular Imaging & Therapeutics at UCSF
- Early and accurate image interpretation and diagnosis
- Patient-centered imaging
- Advanced diagnostic molecular imaging modalities including new PET/CT and PET/MRI methods
- Expertise in both adult and pediatric nuclear and clinical molecular imaging
- Experience in the use of nuclear isotopes (radionuclides) for imaging studies
- On-site cyclotron and a dedicated staff of radiochemists and radiopharmacists
- Experience in comprehensive multi-modality imaging of cancer and advanced nuclear cardiology imaging studies
- The use of cutting edge theranostic agents, which allow both imaging and therapy
Conditions we address
Molecular Imaging and Therapeutics helps doctors to determine the causes of a medical problem based on functional information about tissues, organs or bones (via, for example, a nuclear medicine bone scan). We provide expert diagnosis and treatment including:
- Bones
- Brain
- Benign and malignant tumors
- Cancers
- Coronary artery disease (CAD)
- Endocrine disorders
- Gallbladder
- Heart and vascular diseases
- Lungs
- Lymphoma
- Neuroblastoma
- Neuroendocrine tumors
- Pediatrics
- Prostate cancer
- Renal
- Thyroid disorders / thyroid cancer (Graves' Disease)
- Transplant patients
Molecular Imaging and Therapeutics services
- PET/CT
- SPECT/CT (Tomographic imaging)
- Cardiac PET Imaging
- Ability to Synthesize Radiopharmaceuticals for Studies
- Radiopharmaceutical therapy and theranostics
Who we partner with
- Patients and their families
- Researchers from our own and other institutions
- Donors and other visionaries committed to improving the lives of others
- Referring colleagues, including breast surgeons, cardiologists, cardiothoracic surgeons, medical and radiation oncologists, plastic surgeons, and genetic counselors
Who we are
- Faculty members
- Nuclear medicine fellows
- Postdoctoral fellows
- Nuclear medicine technologists
- Nurses
- Research staff
- Medical and graduate students
Molecular Imaging and Therapeutics Affiliate Faculty
Members of the Chemistry, Probes, & Molecular Therapy research group contribute to the research, educational, and clinical mission of the selection of the Molecular Imaging and Therapeutics division.
- Spencer Behr, MD
- Robert Bok, MD, PhD
- Elias Botvinick, MD
- Myriam Chaumeil, PhD
- Michael Evans, PhD
- Robert Flavell, MD, PhD
- Thomas Hope, MD
- John Kurhanewicz, PhD
- Yan Li, PhD
- Michael Ohliger, MD, PhD
- Miguel Pampaloni, MD, PhD
- Atif Qasim, MD
- Gil Rabinovici, MD
- Sabrina Ronen, PhD
- Youngho Seo, PhD
- Renuka Sriram, PhD
- Henry VanBrocklin, PhD
- Daniel Vigneron, PhD
- Javier Villanueva-Meyer, MD
- Pavithra Viswanath, PhD
- Jane Wang, MD
- David Wilson, MD, PhD
- Benjamin Yeh, MD
- Matthew Zapala, MD, PhD
